xylyx

IN MATRICO™ Drug Discovery

Increasing predictiveness and confidence in drug discovery
for cancer, fibrosis, and other devastating diseases.

Products

Tissue-specific ECM substrates enable high-fidelity disease models that reflect human disease biology.

Services

IN MATRICO™ compound testing services accurately predict in-vivo drug response.

Data Packages

Patient, tissue, and molecular data provide valuable clinical context to inform compound testing design and results.

News

Xylyx Bio Awarded $2.2M NIH SBIR Fast-Track Grant from National Heart, Lung, and Blood Institute

Xylyx Bio has been awarded a Small Business Innovation Research (SBIR) Fast-Track grant from the National Heart, Lung, and Blood Institute (NHLBI) of the National Institutes of Health (NIH) to advance development of an anti-fibrotic drug testing platform that will help scientists discover and test drug candidates for idiopathic pulmonary fibrosis (IPF).

Read More

Xylyx Bio partners with Inventia Life Science to develop tissue-specific, digitally-printed bioinks for drug discovery

Xylyx Bio, a New York-based leader in advanced biomaterials, and Inventia Life Science, a Sydney-based biotechnology company, today announced their strategic partnership following promising results developing more realistic, scalable, and reproducible 3D cell cultures for drug discovery and biomedical research.

Read More

VIVIQ™ Skin Health Launches to Bring Clinical Benefits to Prestige Skincare

Xylyx Bio launched VIVIQ Skin Health, a prestige skincare brand with the world’s first and only skincare product powered by Matrikynes® biotechnology, a clinically proven blend of extracellular matrix peptides designed to bring clinic-worthy results to consumer skincare.

Read More

Xylyx Bio and Cell&Soft Announce positive initial results following Strategic Partnership to Develop Next-Generation in vitro Platforms to Accelerate Cancer Drug Discovery

New  York-based Xylyx Bio, a leader in predictive disease models and tissue-specific extracellular matrix (ECM) products, and Cell&Soft SAS, a French biotech company specializing in innovative soft cell culture plates, today announced positive preliminary results, reaching a key milestone in their partnership to develop more physiologically relevant in vitro cellular models for cell-based assays in oncology.

Read More

What they’re saying

“ We were looking for a product to use for engineering cartilage tissue. We used the TissueSpec® Cartilage ECM Hydrogel to encapsulate chondrocytes within the 3D tissue environment the cells are exposed to in native cartilage. Chondrocytes grew really well, and these tissue constructs have developed mechanical and biochemical properties and histological staining similar to native articular cartilage.”
Bob Nims, PhD, Columbia University